This FTSE 100 stock would’ve tripled my money in 10 years. Can it happen again?

Manika Premsingh holds this FTSE 100 stock in her portfolio already, but is now wondering if it is likely to continue rising like it has in the past. 

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Plenty of high performing stocks are part of the FTSE 100 index. But not every stock is made equal. Some are definitely better buys than others and have managed to reward investors again and again. Like the the healthcare star AstraZeneca (LSE: AZN). If I had bought it 10 years ago, it would have tripled my money by now. 

AstraZeneca’s eye-watering valuation

I know that on the face of it, it comes with risks. A big one is its market valuation. I spend a fair bit of time researching cheap stocks, because they might just have the potential to rise significantly more than pricey ones. And by that argument, AstraZeneca should be an absolute no-go. Right now, it has an unbelievable price-to-earnings (P/E) ratio of 1,510 times as per my calculations based on its recently released full-year earnings report. The only other stock I have seen with such high valuations is Tesla, and there is no way I am about to buy it. 

Scratching the surface

If I dig deeper into this story, however, it turns out that AstraZeneca’s full-year 2021 P/E has risen to crazy levels only because of a massive fall in its reported earnings, which needs to be taken with a healthy measure of salt in my view. That is because the latest drop is driven partly by the company’s acquisition of US-based rare diseases’ focused company Alexion, a move whose potential impact I had wondered about earlier as well. It is also down because of items like restructuring, amortisation, and impairments. 

If I instead consider the core earnings measure, the number that removes the noise and focuses on the earnings from the main business, it is much healthier. And it gives me a P/E of 22 times, which I think is a truer reflection of the company’s valuation. The reported number is too much of an outlier in my view to give any real perspective!

What is really going on with this FTSE 100 stock?

At this valuation, AstraZeneca does not look terrible expensive to me. I mean it is not significantly higher than that for the FTSE 100 at 16 times. And this is a healthy defensive, with a good outlook for the current year. Speaking of its outlook, the company is optimistic despite the fact that its Covid-19 related numbers are expected to weaken as the pandemic’s grip wanes. Its crucial cancer treatments are likely to hold it in good stead over the foreseeable future. And it helps that it is adding to its portfolio of products, like through the acquisition of Alexion. 

I first bought the stock a few years ago, and occasionally buy it on dips even now. It has not disappointed me so far, I look forward to buying more of it in the near future. And holding it for a long time. Because I think it could triple my money over the next decade as well. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh owns AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

1 Warren Buffett stock I’m buying now

Coca-Cola is the fourth-largest holding in Warren Buffett’s Berkshire Hathaway. I’ll explain why I’m following Buffett and buying more.

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

I bought 4,403 Lloyds shares in June and 4,856 in September. Here’s what they’re worth now

Harvey Jones thought he was bagging a FTSE 100 bargain when he bought Lloyds shares on two occasions last year.…

Read more »

Young woman holding up three fingers
Investing Articles

I’m itching to buy these 3 hidden FTSE gems in a Stocks and Shares ISA

Harvey Jones is keen to add these three FTSE 100 companies to his Stocks and Shares ISA before April. Only…

Read more »

Close up of a group of friends enjoying a movie in the cinema
Investing Articles

How I’d try and turn just £1 a day into a fabulous £54,485 passive income for life

By investing small, regular sums in FTSE 100 shares I can potentially generate a huge passive income stream. It won't…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’d aim for a million buying under a dozen shares

Christopher Ruane explains why less could be more when it comes to building a share portfolio if he wants to…

Read more »

Investing Articles

Rolls-Royce shares are up over 1,000% since 2020! Am I too late to buy?

Rolls-Royce shares now cost over tenfold what they did in the firm's 2020 rights issue. Our writer thinks they may…

Read more »

Investing Articles

1 top UK growth stock for my tech portfolio in 2024

Up 30% in just one year, this growth stock looks positioned to continue on the path of substantial gains, according…

Read more »

Buffett at the BRK AGM
Investing Articles

I’d follow Warren Buffett to target effortless passive income

Warren Buffett knows a thing or two about building passive income streams. By learning from the Sage of Omaha, so…

Read more »